1. Home
  2. LARK vs MRSN Comparison

LARK vs MRSN Comparison

Compare LARK & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Landmark Bancorp Inc.

LARK

Landmark Bancorp Inc.

HOLD

Current Price

$27.91

Market Cap

167.8M

Sector

Finance

ML Signal

HOLD

Logo Mersana Therapeutics Inc.

MRSN

Mersana Therapeutics Inc.

HOLD

Current Price

$27.40

Market Cap

138.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LARK
MRSN
Founded
1885
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
167.8M
138.6M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
LARK
MRSN
Price
$27.91
$27.40
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$30.38
AVG Volume (30 Days)
8.4K
235.1K
Earning Date
10-29-2025
11-14-2025
Dividend Yield
2.86%
N/A
EPS Growth
38.73
N/A
EPS
2.84
N/A
Revenue
$64,367,999.00
$33,180,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$9.83
N/A
Revenue Growth
12.95
N/A
52 Week Low
$20.99
$5.21
52 Week High
$29.56
$70.73

Technical Indicators

Market Signals
Indicator
LARK
MRSN
Relative Strength Index (RSI) 58.84 83.13
Support Level $27.26 $27.25
Resistance Level $28.77 $27.70
Average True Range (ATR) 0.92 0.55
MACD 0.04 -0.14
Stochastic Oscillator 39.57 28.80

Price Performance

Historical Comparison
LARK
MRSN

About LARK Landmark Bancorp Inc.

Landmark Bancorp Inc is the bank holding company for Landmark National Bank, which is dedicated to providing quality financial and banking services. The Bank has continued to focus on increasing its originations of commercial, commercial real estate (CRE), and agricultural loans, which management believes will be more profitable and provide more growth for the Bank than traditional one-to-four-family residential real estate lending. In addition, it also invests in certain investment and mortgage-related securities using deposits and other borrowings as funding sources. Its primary deposit gathering and lending markets are geographically diversified with locations in central, eastern, southeast, and southwest Kansas.

About MRSN Mersana Therapeutics Inc.

Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.

Share on Social Networks: